amyotrophic lateral sclerosis
Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
ALS research news briefs, including newly identified roles for TDP43, a new study of the TDP43 mouse, and an ongoing clinical trial of ceftriaxone
Posted on Wednesday, March 23, 2011 - 08:24, By: Margaret Wahl
TDP43 has unexpectedly extensive role
Scientists have found that the protein TDP43 normally influences the synthesis of more than 1,500 other proteins, including itself. Mutations in the gene for TDP43 are a known cause of ALS, and TDP43 is depleted in the nucleus and enriched in the cytoplasm (...
Through MDA's Augie's Quest program, the ALS Therapy Development Institute has been awarded an additional $2 million for drug development research
Posted on Wednesday, March 2, 2011 - 14:13, By: Amy Madsen
MDA has awarded $2 million to the ALS Therapy Development Institute (ALS TDI) in Cambridge, Mass., to help scientists complete the preclinical testing of four promising new compounds in ALS TDI's drug development pipeline.
The grant, made through MDA's Augie's Quest ALS fundraising initiative...
Presentations and panel discussions at ALS TDI's 2010 Leadership Summit focused on the past, present and future of ALS research
Posted on Wednesday, October 13, 2010 - 12:43, By: Amy Madsen
Themes discussed throughout the research symposium included ALS genetics, clinical trials, the role of the immune system in disease onset and progression, biomarkers, and the use of stem cells in ALS therapeutics.
Mice with an SOD1 mutation and an ALS-like disease survived longer after researchers blocked the immune-system protein interleukin-1-beta.
Posted on Thursday, August 12, 2010 - 06:42, By: Margaret Wahl
Elevated levels of an immune-system protein called interleukin-1-beta (IL-1-beta) exacerbates a disease in mice that closely resembles human amyotrophic lateral sclerosis (ALS), and blocking this protein extends survival in these mice, a research team in Germany has found.
The study adds to the...